StreetInsider.com News Articles

Form PRE 14A Theriva Biologics, Inc. For: Oct 09

Fri, 09 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261009/27172044.html

Theriva Biologics' VCN-01 trial results published in Nature Medicine

Wed, 30 Sep 2026 08:01:08 -0400

Theriva Biologics (NYSE American: TOVX) announced that results from its VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer patients were published in Nature Medicine, according to a company statement.

The trial enrolled 112 patients across 14 sites in the U.S. and Spain. Patients in the VCN-01 treatment arm received intravenous VCN-01 seven days prior to the first and fourth cycles of standard-of-care gemcitabine/nab-paclitaxel chemotherapy. The control arm received chemotherapy alone.

Patients treated with VCN-01 combined with chemotherapy showed improved overall survival, progression-free survival, and duration of response compared to those receiving chemotherapy alone, according to the publication.

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Wed, 30 Sep 2026 08:00:00 -0400

- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer -

- Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies -

- The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreatic cancer patients is currently being evaluated in the VIRAGE2 Phase 2a clinical trial -

ROCKVILLE, Md., Sept. 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Wed, 30 Sep 2026 08:00:00 -0400

- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer -

- Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies -

ROCKVILLE, Md., Sept. 30, 2026

Form S-8 Theriva Biologics, Inc.

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968982.html

Form S-8 Theriva Biologics, Inc.

Mon, 24 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968982.html

Theriva Biologics (TOVX) Misses Q2 EPS by 1c

Tue, 11 Aug 2026 09:39:40 -0400

Theriva Biologics (NYSE: TOVX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Theriva Biologics (TOVX) click here.

Theriva Biologics (TOVX) Misses Q2 EPS by 1c

Tue, 11 Aug 2026 09:39:39 -0400

Theriva Biologics (NYSE: TOVX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Theriva Biologics (TOVX) click here.

Form 10-Q Theriva Biologics, Inc. For: Jun 30

Tue, 11 Aug 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26901972.html

Form 10-Q Theriva Biologics, Inc. For: Jun 30

Tue, 11 Aug 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26901972.html

Form 8-K Theriva Biologics, Inc. For: Aug 11

Tue, 11 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260811/26901939.html

Form 8-K Theriva Biologics, Inc. For: Aug 11

Tue, 11 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260811/26901939.html

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Tue, 11 Aug 2026 08:00:00 -0400

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –